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Objectives We describe procedural and clinical outcomes in a high-risk cohort undergoing transcatheter aortic valve re-
placement with early next-generation transcatheter valve and delivery systems.
Background Percutaneous aortic valve replacement is gaining acceptance as a viable option in patients at high surgical risk.
Broader application will require further advances in valve and delivery system technology.
Methods Transarterial aortic valve replacement was attempted in 25 patients (mean age 85 years) determined to be at high
surgical risk due to comorbidities. A new delivery catheter system (RetroFlex 2, Edwards Lifesciences, Irving, Califor-
nia) was utilized in combination with either a balloon-expandable SAPIEN (Edwards Lifesciences) valve or a next-
generation low-profile cobalt-chromium bovine pericardial SAPIEN XT (Edwards Lifesciences) valve.
Results Percutaneous valve replacement was successful in all 25 high-risk patients. Aortic valve area increased from
0.59  0.15 cm2 to 1.60  0.27 cm2. In this high-risk cohort (Society of Thoracic Surgeons and logistic Euro-
SCORE estimates of surgical mortality were 8.9% and 21.0%, respectively), 30-day mortality was 0%.
Conclusions Technical and procedural advances in catheter systems and prosthetic valves designed for percutaneous aortic
valve delivery may contribute to increased procedural success and improved clinical outcomes. (J Am Coll
Cardiol 2009;53:1855–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.075t
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vnitial attempts at percutaneous aortic valve replacement
AVR) were compromised due to the difficulties associ-
ted with vascular passage of a relatively bulky prosthetic
alve compressed onto a standard valvuloplasty catheter
1,2). Subsequent technical and procedural improvements
llowed the development of a more predictable therapy
3). Although outcomes continue to improve, limitations
aortic injury, atheroembolism, difficulty crossing the
ative valve) remain apparent (4). We describe a new
elivery system and next-generation balloon-expandable
alve in a case series of 25 high-risk patients undergoing
ransarterial AVR.
ethods
ercutaneous AVR was approved for clinical use in patients
ith symptomatic aortic stenosis in whom the risk associ-
ted with open heart surgery was considered prohibitive by
team of cardiologists and cardiac surgeons. Written
nformed consent was obtained. Patients were excluded if
rom the Division of Cardiology, St. Paul’s Hospital, University of British Columbia,
ancouver, British Columbia, Canada. Dr. Webb is a consultant to Edwards
ifesciences Inc.r
Manuscript received April 29, 2008; revised manuscript received July 15, 2008,
ccepted July 21, 2008.he diameter of the aortic annulus was 18 or 26 mm as
ssessed by transesophageal echocardiography, if there was
evere iliofemoral arterial disease, or if a reasonable quality
r duration of life was considered unlikely.
Procedures were performed in a catheterization labora-
ory under general anesthesia. Percutaneous femoral artery
uncture was utilized followed by percutaneous suture
pre-closure” (Prostar, Abbott, Boston, Massachusetts) or
urgical cutdown. The basic procedure of transarterial AVR
as been previously described (3,4).
elivery system. The RetroFlex 2 delivery system (Edwards
ifesciences, Irvine, California) incorporates a coaxial nose
one catheter, a balloon catheter, and a deflectable pusher
atheter (Fig. 1). The catheter is advanced through the sheath
nd into the aorta. An articulation control knob allows steering
round the aortic arch and through the central orifice of the
tenotic native valve. The deflectable pusher catheter is re-
racted, and the nose cone is advanced so as to expose the
eployment balloon (Fig. 2). The prosthesis is positioned
ithin the native valve. The deployment balloon is inflated and
eflated while right ventricular burst pacing is used to tempo-
arily reduce transvalvular flow. The balloon is utilized to guide
he withdrawal of the nose cone through the newly implanted
alve. The nose cone and pusher catheter are approximated and
emoved through the delivery sheath.
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Percutaneous AVR May 19, 2009:1855–8Valves. Initial reports of balloon-
expandable valve replacement
utilized a valve constructed from
a stainless steel tubular frame
with equine pericardial leaflets
and a fabric sealing cuff (Cribier-
Edwards, Edwards Lifesciences).
his basic valve design was subsequently modified utilizing
ovine pericardial leaflets and lengthening the sealing cuff
ithout modification of the frame (SAPIEN, Edwards
ifesciences).
A next-generation transcatheter heart valve (SAPIEN
T, Edwards Lifesciences) was utilized in 3 patients. A
obalt-chromium frame permits thinner struts without loss
f structural integrity. Thinner struts and a more open
esign allow for a lower crimped profile (Fig. 3), while
aintaining the valve’s radial stiffness. Bovine pericardial
eaflets are matched for thickness and elasticity and incor-
Figure 1 Diagrammatic Representation
Showing the RetroFlex 2 Catheter System
The catheter system is shown during passage through the aorta (left) and with
the nosecone advanced and flexion catheter withdrawn to allow expansion of
the deployment balloon (right).
Figure 2 Photograph of RetroFlex 2 Catheter
The catheter is shown during introduction (top) and with the
balloon exposed to allow deployment of the prosthesis (bottom).
Abbreviations
and Acronyms
AVR  aortic valve
replacement
IQR  interquartile rangevorate Thermafix anticalcification treatment. The scalloped
eometry and attachment method of the leaflets have been
odified to achieve a naturally closed design and enhance
alve durability (Fig. 4).
The femoral arterial sheath required is determined by the
rimped diameter of the prosthetic valve and its delivery
ystem. A 23-mm SAPIEN valve crimped on the RetroFlex
delivery catheter requires a 22-F internal diameter sheath,
hereas a 26-mm SAPIEN valve requires a 24-F sheath.
hen crimped on the current RetroFlex 2 catheter, the
6-mm next-generation low-profile valve allows use of a
2-F sheath.
tatistics. Continuous variables are presented as mean 
D, medians, and interquartile ranges (IQRs), as appropri-
te. Categorical variables are stated as frequencies and
ercentages. Normality was tested with the Kolmogorov-
mirnov goodness-of-fit test. For comparison of continuous
Figure 3 Low-Profile Next-Generation SAPIEN XT Valve
The thin cobalt-chromium struts and relatively open frame allow a low delivery
profile without loss of radial strength (A). Unlike the SAPIEN valve, the scal-
loped leaflets are closed at rest. The scalloped geometry of the bovine pericar-
dial leaflets results in superior durability as assessed by in vitro testing (B).ariables before and after transarterial AVR, the Student t
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May 19, 2009:1855–8 Percutaneous AVRest was used, and for comparison of groups, a 1-way
nalysis of variance F test was utilized. Categorical variables
ere compared by the Fisher exact test. A 2-sided value of
 0.05 was considered statistically significant.
esults
he RetroFlex 2 system was utilized in 25 patients. Mean
ge was 85 years (IQR: 79 to 88 years). Patients had
Figure 4 Low-Profile Next-Generation Cobalt-Chromium
SAPIEN XT Valve Explanted at 20 Weeks From a Sheep
Tissue growth over the inflow portion of the frame can be seen.
aseline Characteristics of 25 High-Risk Patients
Table 1 Baseline Characteristics of 25 High-Risk Patients
Characteristic
Age, yrs 85 (79–88)
Female sex 13 (52)
New York Heart Association functional class
I 1 (4)
II 2 (8)
III 14 (56)
IV 8 (32)
Diabetes 6 (24)
Coronary artery disease 12 (48)
Severe lung disease 6 (24)
Prior cerebral ischemic event 2 (8)
Peripheral vascular disease 3 (12)
Prior thoracotomy 7 (28)
Prior coronary bypass surgery 6 (24)
Prior angioplasty 10 (40)
Estimated glomerular filtration rate 60 ml/min 10 (40)
Ejection fraction 50% 4 (16)
Mitral regurgitation (moderate or severe) 3 (12)
Pulmonary hypertension 60 mm Hg 6 (24)
Porcelain aorta 3 (12)
Frail and poor mobility 10 (40)
Logistic EuroSCORE (5) 21 (15–30)
STS 8.9 (6.0–12.4)
alues are n (%) or median (interquartile range).s
STS  Society of Thoracic Surgery National Database risk calculator estimated 30-day surgical
ortality.ultiple comorbidities, including prior thoracotomy (28%),
enal insufficiency (40%), porcelain aorta (12%), grade 3 or
mitral regurgitation (12%), severe lung disease (24%), and
evere frailty (40%). Baseline characteristics are presented in
able 1.
Procedural success, defined as implantation of a prosthe-
is at the intended site, was achieved in all patients.
ortuosity of the thoracic aorta, horizontal aortic roots, and
everely stenotic, heavily calcified valves, although problem-
tic with earlier delivery systems, were relatively easily
anaged with the new delivery system. Percutaneous needle
uncture was utilized for femoral arterial access in all
atients and percutaneous suture closure in the majority.
utcomes are presented in Table 2. Society of Thoracic
urgeons and logistic EuroSCORE estimates of operative
0-day mortality were 8.9% and 21.0%, respectively. All
atients remained alive at 30 days.
The SAPIEN valve was utilized in 22 patients and the
ext generation low profile cobalt-chromium SAPIEN
T valve in 3. At discharge, echocardiographic aortic
ean gradient had fallen from 49.3  17.9 mm Hg to
0.6  2.9 mm Hg and effective orifice area had risen
rom 0.59  0.15 cm2 to 1.6  0.27 cm2 (Table 3). No
atient had more than mild valvular regurgitation, and
nly 1 patient had more than mild paravalvular regurgi-
ation (graded moderate). All patients had normal pros-
hetic valve function at 1-month echocardiographic
ollow-up.
iscussion
ranscatheter valve replacement continues to evolve rapidly.
n the initial experience with transarterial AVR, procedural
utcome at 30 Days
Table 2 Outcome at 30 Days
Characteristic n (%)
Procedural success 25 (100)
Nondisabling stroke 2 (8)
Disabling stroke 0 (0)
Myocardial infarction 0 (0)
Ventricular fibrillation 0 (0)
Heart block, new and sustained 0 (0)
Tamponade 0 (0)
Transfusion 3 U 3 (12)
Percutaneous access 25 (100)
Percutaneous closure 16 (64)
Emergent cardiac surgery 0 (0)
Intra-aortic counterpulsation 1 (1)
Femoral–femoral support 1 (4)
Endocarditis 0 (0)
New requirement for dialysis 0 (0)
Death, intraprocedural 0 (0)
Death, 30 days 0 (0)
Death, stroke, or myocardial infarction at 30 days 2 (8)
Death, disabling stroke, myocardial infarction at 30 days 0 (0)uccess was achieved in 78% of patients with a 30-day
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Percutaneous AVR May 19, 2009:1855–8ortality of 11% (3). The current success rate of 100% and
0-day mortality of 0% in 25 high-risk patients is encour-
ging. Technological and procedural improvements as well
s increasing experience likely share responsibility for these
mproving outcomes.
Although mortality was not observed, morbidity was.
he major source of morbidity was related to vascular
ccess. Pre-procedural screening and improved vascular
Figure 5 Photograph of RetroFlex 3 Catheter
More recently the RetroFlex 3 catheter has seen early clinical use. This system
incorporates a shorter fixed nose cone for ease of use and safety. Future modi-
fications in RetroFlex 4 will reduce profile further.
Figure 6 Fluoroscopic Appearance of the Low-Profile
Cobalt-Chromium Next-Generation SAPIEN XT Valve
Aortic angiography shows optimal positioning with no evidence of paravalvular
regurgitation (left). The valve can be seen to be fully and symmetrically
expanded (right).
chocardiographic Valve Function
Table 3 Echocardiographic Valve Function
All Patients (n  25)
Baseline Discharge
Mean gradient (mm Hg) 49.3 17.9 10.6 2.9*
Effective orifice area (cm2) 0.59 0.15 1.6 0.27*
Valvular regurgitation  mild 0 0
Paravalvular regurgitation  mild — 0
p  0.0001 versus baseline; †p  0.05 versus baseline, no differences among groups were obsKanagement appear to be reducing vascular morbidity and
ortality risk (4). Consequently, a major thrust of current
evelopment is to reduce the diameter of the valve and
elivery system. The development of a new, thinner cobalt-
hromium SAPIEN XT valve frame with a more open
esign allows for tighter crimping of the valve and an
mproved delivery profile. Further modification of the de-
ivery system to accommodate this next-generation valve is
xpected to reduce the delivery profile to 18- or 19-F (Fig.
). Such a reduction in profile will likely increase the
opulation of patients amenable to this therapy and improve
utcomes further. The thinner struts of the next-generation
obalt-chromium low-profile device did not appear to result
n a reduction in orifice area (Fig. 6). We have not observed
tructural valve failure in our larger experience with almost
00 valve implants. Comparable or improved durability with
he next-generation valve is anticipated by in vitro testing
ut remains to be clinically demonstrated.
onclusion
dvances in transcatheter valves, delivery systems, and proce-
ural technique may result in improved outcomes and suggest
he potential for a broader role of this therapeutic modality.
eprint requests and correspondence: Dr. John G. Webb,
cLeod Professor of Heart Valve Intervention, St. Paul’s Hospi-
al, 1081 Burrard Street, Vancouver, British Columbia, Canada
6Z 1Y6. E-mail: webb@providencehealth.bc.ca.
EFERENCES
. Cribier A, Eltchaninoff H, Tron C, et al. Early experience with
percutaneous transcatheter implantation of heart valve prosthesis for the
treatment of end-stage inoperable patients with calcific aortic stenosis.
J Am Coll Cardiol 2004;43:698–703.
. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter
implantation of an aortic valve prosthesis for calcific aortic stenosis: first
human case description. Circulation 2002;106:3006–8.
. Webb JG, Chandavimol M, Thompson C, et al. Percutaneous aortic
valve implantation retrograde from the femoral artery. Circulation
2006;113:842–50.
. Webb JG, Pasupati SJ, Humphries K, et al. Percutaneous transarterial
aortic valve replacement in selected high risk patients with aortic
stenosis. Circulation 2007;116:755–63.
. Nashef SA, Roques F, Hammill BG, et al. Validation of European System
for Cardiac Operative Risk Evaluation (EuroSCORE) in North American
cardiac surgery. Eur J Cardiothorac Surg 2002;22:101–5.
SAPIEN Valve (n  22) Next Generation Valve (n  3)
Baseline Discharge Baseline Discharge
49.0 17.9 10.7 3.0* 51.3 17.6 10.0 1.4†
0.58 0.14 1.6 0.28* 0.63 0.21 1.7 0.07
0 0 0 0
— 1 — 0ey Words: aortic stenosis y percutaneous y valve y valvuloplasty.
